Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma

NCT00538005 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Melanoma (Skin)

Interventions

BIOLOGICAL: bevacizumab
DRUG: oxaliplatin
DRUG: sorafenib tosylate

Sponsor

San Diego Pacific Oncology & Hematology Associates